Norges Bank Invests $12.09 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Norges Bank purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 401,495 shares of the biopharmaceutical company's stock, valued at approximately $12,085,000. Norges Bank owned approximately 0.26% of TG Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp grew its holdings in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC bought a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $75,000. Finally, GAMMA Investing LLC lifted its stake in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 2,171 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Remove Ads

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $0.73 during mid-day trading on Friday, hitting $36.71. The company's stock had a trading volume of 2,052,937 shares, compared to its average volume of 3,110,585. The company has a market capitalization of $5.77 billion, a price-to-earnings ratio of -367.06 and a beta of 2.14. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The stock has a fifty day moving average of $35.76 and a 200-day moving average of $31.39.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TGTX. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.